Alector has filed a patent for compositions containing antibodies that specifically bind to a TMEM106B polypeptide. These compositions can be used to prevent, reduce the risk, or treat individuals in need. The patent claims have been canceled. GlobalData’s report on Alector gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alector, Personalized cancer vaccines was a key innovation area identified from patents. Alector's grant share as of September 2023 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for preventing or treating tmem106b-related conditions
A recently filed patent (Publication Number: US20230303681A1) describes an invention related to antibodies that bind to human TMEM106B, a protein associated with various diseases and conditions. The patent claims an isolated nucleic acid that encodes an antibody with specific amino acid sequences for the heavy chain variable region and light chain variable region. The patent also claims a vector containing the nucleic acid and an isolated host cell containing the vector. Additionally, the patent claims a method of producing the antibody by culturing the host cell and recovering the antibody.
Furthermore, the patent claims methods of preventing, reducing risk, or treating individuals with various diseases, disorders, conditions, or injuries by administering the antibody. These include neurodegenerative disorders, disorders characterized by the presence of TDP-43 inclusions, frontotemporal lobar degeneration, frontotemporal dementia, Alzheimer's disease, Lewy body dementia, cognitive impairment, and cancer. The method involves administering a therapeutically effective amount of the antibody to the individual in need.
The patent also describes methods of preventing, reducing risk, or treating individuals with diseases, disorders, conditions, or injuries associated with overexpression or increased activity of TMEM106B. This includes disorders associated with inflammatory cell debris or protein aggregates, abnormal circulating myeloid cells, unhealthy aging, age-related brain atrophy, age-associated traits, age-associated inflammation, age-associated neuronal loss, age-associated cognitive deficits, hypomyelinating disorders, and metastasis. The method involves administering a therapeutically effective amount of the antibody to the individual in need.
The patent further specifies that the antibody can be a monoclonal antibody and can belong to the IgG, IgM, or IgA class. It can also be an antibody fragment, such as Fab, Fab', Fab'-SH, F(ab')2, Fv, or scFv fragment. Additionally, the patent claims that the antibody can be modified to facilitate transport across the blood-brain barrier by including antigens such as transferrin receptor, insulin receptor, insulin-like growth factor receptor, low-density lipoprotein receptor related proteins, diphtheria toxin receptor, CRM197, llama single domain antibody, TMEM 30(A), protein transduction domain, TAT, Syn-B, penetratin, poly-arginine peptide, angiopeptide, basigin, Glut1, CD98hc, or ANG1005.
Overall, this patent describes the development and potential applications of antibodies that target TMEM106B and their use in preventing, reducing risk, or treating various diseases and conditions associated with TMEM106B.
To know more about GlobalData’s detailed insights on Alector, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
